Steminent Biotherapeutics Inc. (TPEX:7729)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Research and Application of Mesenchymal Stem Cells and Related Technologies		941.00K	636.00K	2.12M	51.47M
Total		941.00K	636.00K	2.12M	51.47M

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Taiwan		941.00K	636.00K	1.91M	-
Japan		-	-	213.00K	35.21M
South Korea		-	-	-	16.26M
Total		941.00K	636.00K	2.12M	51.47M

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 28, 2026

Data Sources Report a data error